Topics

Clinical Trials About "Duac Differin Acne Vulgaris" RSS

09:18 EST 25th February 2020 | BioPortfolio

We list hundreds of Clinical Trials about "Duac Differin Acne Vulgaris" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Duac Differin Acne Vulgaris" on BioPortfolio

We have published hundreds of Duac Differin Acne Vulgaris news stories on BioPortfolio along with dozens of Duac Differin Acne Vulgaris Clinical Trials and PubMed Articles about Duac Differin Acne Vulgaris for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Duac Differin Acne Vulgaris Companies in our database. You can also find out about relevant Duac Differin Acne Vulgaris Drugs and Medications on this site too.

Showing "Duac Differin Acne Vulgaris" Clinical Trials 1–25 of 504

Extremely Relevant

Trial for the Clinical Evaluation of the Quality of Life of the Subject, the Efficacy and the Tolerance of Duac® Gel Against Differin® Gel in the Topical Treatment of Mild to Moderate Acne Vulgaris

The objectives of this clinical trial are to compare the quality of life of the subjects, the efficacy and the tolerance of Duac® Gel (gel formulation with a combination of clindamycin phosphate [equivalent to 1% clindamycin] and 5% benzoyl peroxide), applied once daily, against Differin® Gel (gel with 0.1% adapalene), used once daily, in the treatment of mild to moderate acne vulgaris.


Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris

This study is to determine the efficacy and safety of 12 week treatment with Differin® Gel 0.3% applied in the evening, in combination with Duac® (Clindamycin/Benzoyl Peroxide Gel) applied in the morning, in Subjects with Acne vulgaris.

Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris

The purpose of this research study is to see how well the drug works for subjects who have acne. Adapalene 0.1% (Differin) will be used in this study to treat your acne. Differin is approved by the Food and Drug Administration (FDA) to treat acne.


A Study to Evaluate the Absorption of Clindamycin Following the Use of Clindamycin 1%-Benzoyl Peroxide 3% Gel, Duac Topical Gel, and Duac Once Daily Gel in Subjects With Acne Vulgaris

The purpose of this study is to determine and compare the bioavailability of clindamycin and clindamycin sulfoxide from repeated applications of Clindamycin 1%-Benzoyl Peroxide 3% Gel, Duac Topical Gel, and Duac Once Daily Gel under maximal-use conditions in subjects with acne.

Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris

To evaluate the therapeutic equivalence and safety of Adapalene Gel 0.3% (Aleor Dermaceuticals Limited, India) and Differin® (Adapalene) Gel 0.3% (Galderma Laboratories, LP USA) in the treatment of acne vulgaris.

Evaluation of the Effectiveness, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Treatment of Facial Acne Vulgaris

The purpose of this study is to compare the effectiveness of two marketed products in subjects with facial acne vulgaris

Study Comparing 0.3% Adapalene Topical Gel to Differin® 0.3% Adapalene Topical Gel

Marketed by Galderma Laboratories, L.P., Differin® (adapalene 0.3% topical gel) is a safe and effective topical therapy used for the treatment of acne vulgaris. Actavis Mid-Atlantic LLC has developed a generic formulation of adapalene 0.3% topical gel and the current study is designed to evaluate the safety and efficacy of this formulation.

Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne

To determine the efficacy and safety of 12 weeks of treatment with Differin Gel, 0.1% compared to 12 weeks of treatment with Tazorac Cream, 0.1% and compared to 6 weeks treatment with Differin Gel, 0.1% followed by 6 weeks of treatment with Tazorac Cream

DUAC® Early Onset Efficacy Study in Japanese Subjects

This is a multicentre, randomized, single-blind (investigator is blinded), active (the combination therapy of adapalene [ADA] and clindamycin [CLDM])-controlled and parallel-group study in Japanese subjects with facial acne vulgaris. The purpose of this study is to evaluate the efficacy, safety and tolerability of CLDM 1 percent (%)-benzoyl peroxide 3% (Duac®: trademark owned by GlaxoSmithKline) once daily fixed dose combination gel versus combination therapy of ADA 0.1% gel a...

Evaluation of Topical Application of BMX-010 in Subjects With Acne Vulgaris.

This is an exploratory Phase 2 trial of BMX-010 in patients with Acne Vulgaris which will be conducted in two parts. Up to 210 subjects with Acne Vulgaris will be enrolled.

Decreasing Severity of Acne Vulgaris After the Use of a Combination of Anti-Acne Cream

This study was conducted to see whether there was a decrease in the degree of acne vulgaris / pimple, to find out what proportion of respondents experienced a decrease in severity and who did not experience a decrease in the severity of acne vulgaris after the use of an anti-acne cream combination containing active ingredients such as; Tretinoin 0.05% (derivatives of Vitamin A), Clindamycin 5% (antibiotics), and Dexamethasone 0.05% (anti-inflammatory) for 1 month of use.

A Clinical Study Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris

The purpose of this study is to assess the effectiveness of IDP-110 in treating patients with acne vulgaris.

Analysis of Adherence & Associated Factors in Teenagers Undergoing Treatment of Acne Vulgaris With Differin® Gel 0.1%

The primary objective of this study is to investigate potential differences in treatment adherence by teenagers among four interventions during treatment for acne.

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

This study is to evaluate the therapeutic equivalence and safety of Taro Product to RLD in the treatment of acne vulgaris.

Polymorphism of Extrapituitary Promoter of PRL Gene and Relationships With Serum Prolactin Levels in Acne Vulgaris.

Acne vulgaris is one of the most common skin diseases. It is a disease of the pilosebaceous units, clinically characterized by seborrhea, comedones, papules, pustules, nodules and, in some cases, scarring.

Apelin12 in Acne Vulgaris

Acne vulgaris is a common chronic inflammatory disease of the pilosebaceous unit which is characterized by the formation of non-inflammatory open and closed comedones and inflammatory papules, pustules, nodules and cysts. It is a multifactorial disease that affects mostly adolescent population. Acne appears very early in puberty during the preteen years, often before menarche in girls. Because many adolescents have acne, it is difficult to predict which individuals are prone t...

Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation

Residual post-inflammatory hyperpigmentation (PIH)from acne is disturbing to individuals with skin of color. Finacea has been anecdotally known to be beneficial in resolving PIH related to acne vulgaris. However, it has not been clinically tested for this purpose. The current study will investigate the efficacy and safety of Finacea in the treatment of acne vulgaris and PIH.

Efficacy Study in Patients With Acne Vulgaris.

Safety and efficacy study in patients with acne vulgaris

Evaluation of the Presence of Enthesitis in Patients With Acne Vulgaris

Acne vulgaris is an inflammatory disease of the pilosebaceous unit, affecting about 85% of the young population. In the studies p. acne is a potent stimulator of the release of IFN-gamma (IFN-)) and IL-17 from CD4 + T cells, and the presence of IL-17 + cells in the perifollicular infiltrate has been shown in biopsies of inflammatory acne lesions. Therefore, acne is thought to be a Th17-related disease (1). In this study ; We aimed to evaluate the presence of enthesitis in pati...

A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris

The purpose of this study is to assess the safety and effectiveness of IDP-107 in treating patients with acne vulgaris.

Multiple Arm Study of Sebacia Microparticles in the Treatment of Acne Vulgaris

Prospective, multicenter study with multiple arms to examine the safety and effectiveness of the Sebacia Acne Treatment System for the treatment of acne vulgaris.

Aczone Gel 7.5% in the Treatment of Acne Vulgaris in Patients With Skin of Color

Acne vulgaris is a common skin disease characterized by inflammatory papules, pustules, and comedones that is prevalent in men and women of color. Research has demonstrated that Aczone ® (dapsone) gel, 7.5% used once daily is effective, safe, and well-tolerated for the treatment of acne in both men and women; however, limited data is available regarding its efficacy and safety in skin of color (SOC). The current study aims to investigate the therapeutic impact of Aczone gel 7....

Six Months Evaluation of Next Science Acne Creams on Facial Acne in Adult Females.

To assess facial acne vulgaris clinical and psychological outcomes by measuring differences in lesions counts, investigator global assessment, and subjects quality of life scores over 6 months in adult females treated with Next Science™ acne cream 2x or Next Science™ acne cream 1x in a double blind manner.

Bioequivalence Study of Two Treatments in the Treatment of Acne Vulgaris on the Face

To compare the safety and efficacy of Perrigo's product to an FDA approved product for the treatment of Acne Vulgaris

DMT310-003 Topical in the Treatment of Acne Vulgaris

The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris.


More From BioPortfolio on "Duac Differin Acne Vulgaris"

Quick Search